Approval for NanoViricides' NV-387 Phase II Clinical Trial in DRC

NanoViricides, Inc. has announced that it received clearance from the National Ethics Committee of the Democratic Republic of Congo to proceed with a Phase II clinical trial application for NV-387. This broad-spectrum antiviral drug targets MPox disease, caused by hMPXV infection. This marks a pivotal step for further regulatory filings with the Ministry of Public Health in DRC.

The study aims to assess the safety and efficacy of NV-387, which is already noted for its effectiveness in animal models against viruses like influenza and coronavirus. Notably, no current drug effectively treats hMPXV infection. NanoViricides emphasizes NV-387's unique mechanism, mimicking host cells to trap and destroy viruses, potentially revolutionizing antiviral treatment.

The trial will be conducted at the University of Kinshasa's Medical Hospital, led by a principal investigator. The endeavor aligns with a growing need for more robust antiviral defenses, highlighted by recent MPox outbreaks in Africa.